reviewed april 2026|next review october 2026|88 physicians psi has verified|230 published studies
Thymalin
Thymalin is a polypeptide complex extracted from calf thymus gland, used clinically in Russia and Eastern Europe for immune restoration, containing a mixture of thymic peptides rather than a single defined molecule.
Evidence landscape: 230 published studies
230 published items. 22 human studies and 135 animal studies.
- 22 Human
- 135 Animal
- 43 Reviews
- 30 Other research
Not FDA-approved and not approved by any Western regulatory agency. Used clinically in Russia and Eastern Europe for decades as an immune restoration therapy. Available as a research compound outside of Russia.
230 published studies including 22 human studies and 135 animal studies. Human data comes primarily from Russian clinical literature. Western-standard randomized controlled trials have not been published.
Contains a mixture of thymic peptides that promote T lymphocyte differentiation and maturation. Normalizes the ratio of T-helper to T-suppressor cells and enhances phagocytic activity. As a crude extract rather than a single defined molecule, the active components are not fully characterized.
PSI Assessment
Used clinically in Russia and Eastern Europe for decades, thymalin occupies an unusual position: it has a longer clinical use history than most peptides in this library, but the evidence base does not meet Western regulatory standards. It is a polypeptide complex extracted from calf thymus gland, meaning it contains a mixture of thymic peptides rather than a single defined molecule. Russian clinical studies report improvements in T-cell function and immune recovery in immunocompromised patients. A 15-year observational study by Khavinson and Morozov reported reduced mortality in elderly patients. Western-standard randomized controlled trials have not been published.
Used clinically in Russia for decades as an immune restoration therapy. A crude thymic extract, not a single defined molecule. Western-standard randomized controlled trials have not been published.
The mechanism involves providing exogenous thymic peptides that promote T lymphocyte differentiation and maturation. The thymus gland, which sits behind the breastbone, is where T-cells are trained to recognize threats. The thymus shrinks significantly with age (thymic involution), which is why immune function declines in older adults. Thymalin provides a fraction of the peptides the thymus naturally produces. However, because thymalin is a crude extract rather than a single defined molecule, the specific active components and their concentrations are not fully characterized. This distinguishes it from thymosin alpha-1, which is a single defined 28-amino-acid peptide with broader international validation.
What the evidence supports
Thymalin promotes T lymphocyte differentiation and maturation in both animal models and Russian clinical studies. It has been used clinically in Russia and Eastern Europe for decades as an immune restoration therapy. Russian clinical reports describe improvements in T-cell counts and immune function in immunocompromised patients. The thymic origin and immune-supportive mechanism are biologically plausible.
What is not yet established
Whether thymalin produces clinically meaningful immune restoration by Western randomized controlled trial standards. The active peptide components within the crude extract have not been fully characterized. Whether thymalin offers advantages over the single defined molecule thymosin alpha-1. Independent replication of Russian clinical findings.
Research Evidence
The findings below cover what Russian clinical use has established and where the evidence does not meet Western standards.
Evidence by condition
Evidence dimensions across thymalin research areas. Immune restoration and immune aging have Russian clinical data. Independent Western replication is absent across all indications.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Immune Restoration | ||||
| Immune Aging |
Russian clinical literature reports immune parameter improvements including normalized T-cell subpopulations and enhanced phagocytic activity in immunocompromised patients and elderly adults. Thymalin has been used clinically in Russia and Eastern Europe for over three decades.
The clinical use history is extensive by volume. However, the studies do not meet Western randomized controlled trial standards. Most are observational or use designs that Western regulatory agencies would consider insufficient for approval.
A 15-year observational study by Khavinson and Morozov (2003) followed elderly patients receiving thymalin and reported improvements in immune markers and reduced mortality in the treated group.
This is the most cited thymalin study. The observational design limits causal conclusions. The study has not been independently replicated in a Western clinical setting.
Thymalin is part of the Khavinson bioregulatory peptide program that also produced epitalon, pinealon, and other tissue-targeted peptides. The bioregulator concept proposes that short peptides can regulate gene expression in specific target tissues.
The broader bioregulator program provides context for thymalin's development. The concept is systematically developed within Russian institutions but has not been independently validated by Western research groups.
22 Human|135 Animal|43 Reviews
View all 230 indexed studiesHow Thymalin Works
Thymalin is a polypeptide complex, which means it is a mixture of small protein fragments rather than a single defined molecule. It is extracted from calf thymus gland, the organ behind the breastbone that trains immune cells called T-cells.
Provides thymic peptides that help train and restore the immune system.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Thymalin is a crude polypeptide fraction extracted from calf thymus tissue. It contains a mixture of thymic peptides that regulate T-lymphocyte maturation and differentiation through mechanisms that are not fully characterized at the molecular level. Russian studies report normalization of T-helper to T-suppressor cell ratios, enhanced phagocytic activity, and modulation of cytokine production. The active peptide components within the mixture have not been individually identified and characterized to the standard of a single defined molecule like thymosin alpha-1.
What is Thymalin being studied for?
Researchers are studying Thymalin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Thymalin overall. This means a compound can have human studies for one condition but only animal data for another.
Immune Restoration
·Animal StudiesRussian clinical data shows improved immune parameters in immunocompromised patients. Multiple reports describe T-cell count and function improvement.
Limitations: No Western-standard randomized controlled trials. Russian clinical designs do not meet FDA or EMA trial requirements. Independent replication is absent.
Immune Aging
·Animal StudiesUsed for age-related immune decline in CIS countries. The 15-year Khavinson observational study reported reduced mortality in elderly patients.
Limitations: Observational design limits causal conclusions. The study has not been replicated in a Western clinical setting.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not approved by any Western regulatory agency. Used clinically in Russia and Eastern Europe under different regulatory frameworks.
Availability: Available as a research compound outside of Russia. Clinical use in Russia is through the domestic healthcare system.
Class context: Russian clinical data reports a favorable safety profile with minimal side effects over decades of use. As a crude thymic extract, batch-to-batch consistency cannot be guaranteed to the standard of a synthetic defined molecule.
Russian clinical data spanning decades reports a favorable safety profile with minimal side effects in thousands of patients. However, Western-standard safety data from controlled trials is limited. As a thymus-derived extract, the theoretical safety profile is favorable, but long-term effects and interactions with Western medications have not been systematically studied.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Thymalin discussion.
Comparison and Related Research
Thymalin is most often compared with other thymus-derived immune peptides. The comparisons below outline how each differs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A review of two key peptide bioregulators developed in Russian gerontology research. Summarized data from clinical observations spanning over 15 years, documenting the effects of thymalin on immune function restoration in elderly patients. Reported improvements in T-cell subsets and reduced mortality in long-term follow-up cohorts.Khavinson VKh., 2002 in Adv Gerontol. View on PubMed
- 2.Evaluated thymalin as an adjunctive therapy in the complex treatment of COVID-19 patients, based on its established immunomodulatory properties. The study examined the effects of thymalin on hematopoietic stem cell differentiation and immune cell recovery in the context of acute viral infection and immune dysregulation.Khavinson VK et al., 2021 in Stem Cell Rev Rep. View on PubMed
- 3.A foundational review of natural thymic peptides including thymalin, covering their isolation from bovine thymus, biochemical characterization, and clinical applications. Summarized immunopharmacological data showing thymalin's ability to restore T-lymphocyte function in immunodeficient states, based on studies conducted at the Institute of Bioregulation and Gerontology.Morozov VG & Khavinson VKh., 1997 in Int J Immunopharmacol. View on PubMed
- 4.Reviewed decades of research on peptide bioregulators including thymalin and epithalamin in the context of aging and age-related disease. Presented data from long-term clinical observations suggesting that periodic courses of thymalin administration were associated with reduced mortality from cardiovascular disease, cancer, and respiratory illness in elderly patient cohorts.Anisimov VN et al., 2010 in Biogerontology. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.